Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MegaMOST biology-driven targeted therapy in advanced/metastatic cancers
2023-510567-35-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avapritinib, siremadlin, regorafenib, ribociclib, alectinib and 3 more in Nonhematologic neoplasms and solid tumor (7 cohorts), sponsored by Centre Léon Bérard. Primary endpoint: Progression-free rate at 3 months (3M-PFR). Planned start Sep 2024; status: authorised.
02
Drugs
avapritinibsiremadlinregorafenibribociclibalectinib
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on 2023-510567-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510567-35-00.